Despite EPS growth outpacing share price increases, the mark...

Despite EPS growth outpacing share price increases, the market is cautious towards the stock. Zhejiang Jingxin Pharmaceutical's 17% return is near the market's -17% return. If fundamentals stay strong, the share price drop could be an investment opportunity.